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Abstract 
An animal model in which the human immune system can be reconstituted is necessary 
to study acquired immunity in vivo. We report here a novel model, the 
NOD/SCID/JAK3null mouse, for the human immune system’s development. Newborn 
mice transplanted with human cord blood CD34+ cells intrahepatically, developed 
human T and B cells, and myeloid and plasmacytoid dendritic cells. The T and B cells 
had a naïve to memory phenotype, and included plasma cells. The human acquired 
immune system can be reconstituted from CD34+ cells in NOD/SCID/JAK3null mice. 
This model is a powerful tool for the study of human immunity.  
 
Key Words: hematopoietic stem cell, immunodeficient mice, CD34, transplantation 
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1 Introduction 
Xenotransplantation of human cells into immunocompromised mice has become an 
invaluable tool for studying the function of the human hematopoietic and immune 
systems [1, 2]. NOD/SCID mice have been widely used for the evaluation of human 
hematopoietic stem cell activity, because they exhibit deficiencies in NK cell activity, 
macrophage and DC function, and complement activation as well as T and B cell 
deficiencies. Recent advances have revealed that the complete abolishment of NK cell 
activity by anti-NK antibody treatment or intercrossing with NK defective genetically 
modified mice results in a high degree of engraftment with human hematopoietic cells 
and T cell development. Notably, recently established NOD/SCID/common γ chain 
knockout (γc-/-) and Balb/C-Rag-2-/-γc-/- mice offered superior engraftment capacity 
[3-5].  
       JAK3, a tyrosine kinase crucial for mediating signaling from the common 
γ-chain of cytokine receptors, is limited to cells that actively participate in the immune 
response to allografts [6]. Recent tests in stringent preclinical studies suggest that JAK3 
inhibitiors are effective in preventing of allograft rejection with a narrow side-effect 
profile [7].  On the basis of these findings, NOD/SCID were crossed with JAK3null 
mice [8] to produce a novel strain, NOD/SCID/JAK3null, resulting in a complete lack of 
T, B, NK, and NKT cell function. We successfully reproduced myelo-lymphoid 
maturation by injecting human cord blood-derived CD34+ cells into the liver of 
newborn NOD/SCID/JAK3null mice. Our data show that the NOD/SCID/JAK3null 
newborn system provides a valuable tool with which to reproduce human 
hemato-lymphoid development. 
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2 Materials and methods 
2.1 Mice 
The NOD/SCID/JAK3null strain was established by backcrossing JAK3 null mice [8] with 
the NOD.Cg-Prkdcscid strain for 10 generations. All experiments were performed 
according to the guidelines of the Institutional Animal Committee of Kumamoto 
University. 
2.2 Cell preparation and transplantation 
Umbilical cord blood cells were collected during normal full-term deliveries after 
obtaining informed consent, according to institutional guidelines approved by The 
Faculty of Medical and Pharmaceutical Sciences, Kumamoto University. CD34+ cells 
were isolated using the CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Sunnyvale, 
CA). The purity of the CD34+ cells after isolation was >90 %, and contamination of 
CD3+ cells was less than 5%.  The CD34+ cells (5x104) were transplanted into the liver 
of irradiated (1.2 Gy) newborn mice. 
2.3 Flow cytometry 
Mouse spleen cells were stained with DX5-FITC (pan NK marker), mCD122 
(IL-2Rβ)-PE, mCD19-APC and mCD3-PE/Cy7 (eBiosciences, San Diego, CA) to 
detect the murine lymphocytes. Eight to sixteen wks after transplantation, peripheral 
blood samples were obtained from the retroorbital sinus. At the time of sacrifice, the 
thymus, the spleen and BM were collected, stained with mAbs for differentiation 
antigens, and analyzed using LSR II (BD Biosciences, San Jose, CA). The mAbs used 
were human (h) CD3-APC, hCD4-FITC, hCD11c-APC, hCD33-FITC, hCD34-PE, 
hCD45-FITC, and mCD45.1-PE (BD Biosciences, San Diego, CA), hCD3-PE/Cy7, 
hCD20-PE, hCD38-PE, hCD56-PE, hCD123-PE, and hCD138-FITC (eBiosciences), 
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hCD8-PB, hCCR7-PE, hCD19-PB, hCD27-APC, and hCD45-PB (Dako Cytomation, 
Glostrup, Denmark), BDCA-1(CD1c)-PE, BDCA-2(CD303)-FITC, 
BDCA-3(CD141)-FITC  (Miltenyi Biotech), IgD-FITC (Sigma, St. Louis, MO), and 
hCD45RA-ECD (Beckman Coulter, Fullerton, CA). Data were analyzed with FlowJo 
(Tree Star, San Carlos, CA).  
2.4 Cytotoxicity assay 
The cytotoxic activity of the murine NK cells was measured by flowcytometry-based 
cytotoxicity assay with CFSE-labeled Yac-1 cells and propidium iodide (PI) as 
described by Marcusson-Stahl et al. [9,10]. Briefly, target Yac-1 cells were stained with 
2 μM of fluorescence labeling reagent, 5-(6)-carboxy-fluorescein succinimidyl ester 
(CFSE, Molecular Probes, OR) as described in manufacturer’s instruction. Fifty μl 
aliquots of CFSE-labeled Yac-1 cells (1x105cell/ml) were placed in 5-ml 
round-bottomed tubes, and 400 μl of two-fold serial diluted mononuclear cells from 
spleen was added into the tubes as effector cells. Effector or target cells alone were used 
as negative controls. After 4 h incubation at 37°C, 50 μl of 20 μg/ ml PI was added and 
cells were incubated for an additional 15 min. Target cells in FSC (forward scatter) vs. 
SSC (side scatter) dot plots were gated, and CFSE and PI were measured by LSR II 
flowcytometer. Cytotoxic activity was calculated as follows: A/(A+B)x100-C (%), 
where A is the percentage of PI+EGFP+ cells; B is the percentage of PI-GFP+ cells at 
each E/T ratio; C is the percentage of spontaneous PI+ cells without effector cells 
(A/(A+B)x100 (%) at E/T ratio =0). 
2.5 Histologic analysis 
Tissue samples were fixed with 10% neutral-buffered formalin embedded in paraffin, 
cut into 4-μm sections, and immunostained with mouse anti-CD19, anti-CD3, and 
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antiCD4 antibodies (Dako Cytomation, Carpinteria, CA). After rinsing, the sections 
were incubated with goat anti-mouse-Ig horseradish peroxidase complex (Nichirei, 
Tokyo, Japan) for 30 min and visualized with the use of 3,3’-diaminobenzidine (DAKO, 
Glostrup, Denmark) in 0.05M acetate buffer containing 0.015% H2O2. 
2.6 Proliferative responses to PHA and human IL-2. 
Spleen cells of englafted mice were aseptically prepared as single-cell suspension. The 
cells were cultured in RPMI-1690 containing 20% human AB plasma with PHA (1 
μg/ml) or human IL-2 (200U/ml. Peprotech,Rocky Hill, NJ) at 3x105 cells/100μl in 
microtiter plate. After incubation for 4 days, Tetrazolium dye methylthiotetrazole 
(MTT,0.5 mg/ml final conc.) (Sigma) was added to each well. After 3 hrs of additional 
incubation, 100μl of a solution containing 10% SDS plus 0.01N HCl was added to 
dissolve the crystal. The absorption values at 570 nm were determined with an 
automatic ELISA plate reader (Multiskan, Thermo ElectronVantaa, Finland). 
 
3 Results and Discussion 
3.1 Development of severe immunodeficient NOD/SCID/JAK3null mice 
The NOD/SCID/JAK3null mice were established by backcrossing C57BL/6- JAK3null 
mice [8] with NOD/SCID mice for 10 generations. Flow cytometric analysis a complete 
absence of CD3+ T cells and NKT cells, CD19+ B cells, and DX5+CD122(IL-2Rβ)+ NK 
cells in the spleen (Figure 1A).  NK cell activity was also hardly detectable in 
NOD/SCID/JAK3null mice in functional examinations (Figure 1B). NOD strain is 
known to have functional defects for macrophages and dendritic cells, and compliment 
deficiency [1, 2]. Thus, NOD/SCID/JAK3null mice have severely impaired immunologic 
function. 
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3.2 Early T cell reconstitution in NOD/SCID/JAK3null mice 
To establish the human hemolymphoid system, newborn NOD/SCID/JAK3null mice 
were transplanted intrahepatically with 5x104 CD34+ CB cells. Peripheral blood was 
collected at various intervals for up to 16 wks, and analyzed by flow cytometry for the 
presence of human cells expressing the common human leukocyte antigen CD45 and 
the T lineage marker CD3. Seven wks after transplantation, human CD45+ cells were 
already detected (53.6 ±16.2 %) (Figure 2A, B), though most of them were CD19+ B 
lymphocytes (data not shown), and only a few CD45+CD3+ T lymphocytes (1.2 ± 0.4 % 
of hCD45+ cells ) were observed. However, human T lymphocytes began to emerge and 
proliferate after 12 wks and made up to 62.8 ±19.5 % of the CD45+ cells at 16 wks. 
Representative profiles of CD3+ cell kinetics from the same individual 
NOD/SCID/JAK3null mice are shown in Fig 2B. The reconstitution of T cells occurred 
earlier in the in NOD/SCID/JAK3null newborn system than in the adult recipient system, 
where it usually takes more than 13 wks [3]. 
 
3.3 Human acquired immune system reconstitution from CD34+ cells in 
NOD/SCID/JAK3null mice 
At 16 wks after transplantation, the thymus, the spleen and bone marrow were harvested 
and analyzed by flow cytometry. Myeloid differentiation from cord blood-derived 
hematopoietic stem cells was observed in the bone marrow of the transplanted 
NOD/SCID/JAK3null mice, including CD34-CD33+ myeloid cells (Figure 3A), CD14+ 
monocytes (data not shown), and CD34+ hematopoietic stem cells. Human CD45+ cells 
comprised 64.2 ± 11.5 % of the spleen cells of engrafted NOD/SCID/JAK3null mice. 
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The human cells were mainly CD19+ B cells and CD3+ T cells with a few CD56+CD3- 
NK cells and CD56+CD3+ NKT cells. To further characterize the T lymphocytes 
emerging in the NOD/SCID/JAK3null mice, cells harvested from thymus and spleen 
were analyzed for T cell markers. All thymi contained double-positive, as well as CD4 
and CD8 single positive, T cells (Fig. 3C). Based on the expression of CD45RA and 
CCR7, both human CD4+ and CD8+ T cells can be classified as naïve 
(CD45RA+CCR7+), central memory  (CD45RA-CCR7+), effector memory  
(CD45RA-CCR7-), and terminally differentiated (CD45RA+CCR7-) cells with different 
homing and effector capacities [11, 12]. All these fractions were observed in the spleen 
of transplanted mice. These results demonstrate that human T cell progenitors derived 
from CD34+ cells can proliferate and differentiate into mature T cells in the 
NOD/SCID/JAK3null thymic and splenic microenvironment.  
As for the development of B cells, 77.8 ± 10.2 % of human CD45+ cells in the bone 
marrow were CD19+ B cells. Both immature CD20-negative and mature CD20-positive 
CD19+ B cells were detected in bone marrow of engrafted mice (Figure 3D).  In the 
secondary lymphoid tissue, CD38 and Ig-D have been useful in classifying important 
developmental stages in the pathway from naïve to memory B cells (Bm1-Bm5) [13]. 
All of these stages of B cells were detected in spleen of reconstituted mice. Moreover, 
CD138+CD38+CD27+ plasma cells were detected in bone marrow and spleen, indicating 
that full B cell maturation occurred in reconstituted NOD/SCID/JAK3null mice. Human 
DCs can be divided into CD11chigh myeloid DCs (MDC) and CD123+CD303+ 
plasmacytoid DCs [14]. CD11chigh myeloid DCs are subdivided into MDC1 and MDC2 
by the expression of CD1c and CD141. All three subsets were present in BM and spleen 
of reconstituted mice. Immunohistochemical staining for the expression of CD20, CD3, 
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and CD4 showed that human lymphocytes in the spleen of reconstituted mice possessed 
follicular structures (Figure 3F).  
Next, we cultured the unseparated splenocytes with PHA or human IL-2. As shown in 
Figure 4, splenocytes from these engrafted mice showed a vigous proliferative response 
to these T cell mitogens. Although we observed human T cell proliferation with 
mitogen or human IL-2, it is still unknown whether generated T cells have fully 
functional or not. Indeed, low or absent immune response were observed in 
HIV-1-exposed immunodeficeint mice transplanted with human CD34+ cells [15-17], 
which is explained by insufficient MHC selection of human T cells in the mouse 
thymus and possible lack of some cross reactive cytokines and chemokines in the 
xenogenic environment [18]. This speculation is supported by the fact that 
co-transplantation of human fetal/liver tissues and human CD34+ cells enabled the mice 
to induce the antigen-specific T-cell response and T cell dependent antibody production 
[19]. Detailed analysis and additional ingenuity is needed to induce the functional 
human immune response. 
The Rag-2-/-γc-/- newborn, and NOD/SCID/γc-/- adult and newborn models have already 
provided definitive evidence that functional T cells, B cells, and DCs can develop from 
hematopoietic stem cells in immunodeficient mice [3-5], which is recently called 
“humanized mice” [1,20]. Consistent with these previous models, the 
NOD/SCID/JAK3null newborn model provided full T and B cell maturation as well as 
DC development. The engrafted mice looked healthy and there were no signs and 
symptoms of apparent xenogenic graft versus host disease (GVHD) until 6 months after 
birth, which is also consistent with previous models [3, 21]. Then the mice were 
gradually going to die after 6 months with unknown reason. Further histological 
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examination is needed to clarify the cause of death including the late occurring GVHD 
or the influence of irradiation at the time of birth. There are two advantages to our 
NOD/SCID/JAK3null newborn model. First, T cell ontogeny occurs earlier than in adult 
models. The full T cell reconstitution takes 12 wks after birth in our model (Figure 2), 
whereas adult models take 23 wks (Transplantation into 7-wk-old adult mice and 
reconstitution takes 16 wks) [3]. This is extremely important for enabling long term 
experimentation because the life span of the NOD/SCID strain and irradiated mice is 
relatively short [22,23]. Second, it is relatively easy to transplant the hematopoietic stem 
cells into newborn liver via the cutaneous rather than intravenous route [3, 5]. In 
addition, since relatively small number of CD34+ cells (5x104/mouse) can reconstitute 
the human hematopoietic and immune system in the NOD/SCID/JAK3null mice 
reproducibly, a single human stem cell donor can seed sufficient number of mice for 
testing novel therapeutic strategies such as proof-of-concept mechanistic models and 
models of human infectious disease. 
In summary, we showed that the NOD/SCID/JAK3null newborn system efficiently 
supports the development of human B and T lymphocytes from cord blood-derived 
CD34+ cells, passing through physiological developmental intermediates, and the 
development of human dendritic cells. NOD/SCID/JAK3null mice are a powerful and 
versatile tool that can be used to analyze the human hematopoietic and immune systems 
in response to infection, cancer, and drug regimens without putting patients at risk.  
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Figure Legends 
 
Figure 1. Lymphocytes and NK cell activity in NOD/SCID/JAK3null mice.  
(A) Spleen cells from mice were stained with DX5-FITC (pan NK marker), 
CD122(IL-2RB)-PE, CD19-APC and CD3-PE/Cy7. No NK T, and B cells were 
observed in the spleens of  NOD/SCID/JAK3null mice. (B) Absence of NK activity in 
NOD/SCID?JAK3null mice. Spleen cells from Balb/c, NOD/SCID, and 
NOD/SCID/JAK3null mice were used. The formula for percentage cytotoxicity is 
described in “Materials and methods”. Each value represents the mean of data from four 
mice.  
 
Figure 2. Reconstitution of human T lymphocytes in CD34+ cell-engrafted 
NOD/SCID/JAK3null recipients. 
(A) Kinetics of human cells in NOD/SCID/JAK3null newborn mice (a litter, n=8) 
transplanted with human cord blood CD34+ cells. Peripheral blood cells were collected 
at various intervals from CD34+ cell-transplanted mice and stained with anti-mouse 
CD45.1, and anti-human CD45, CD3, and CD19.. The cells were then analyzed by flow 
cytometry. Human hematopoietic cells were distinguished from mouse cells by the 
expression of human CD45. CD3+ cells among the human CD45+ cells were considered 
as human T lymphocytes. (B) Representative profiles of CD45+CD3+ peripheral blood 
cells in an individual NOD/Scid/Jak3null newborn mouse transplanted with human cord 
blood CD34+ cells. A representative results from 5 independent experiments. 
 
Figure 3. Analysis of human hematopoietic cells in NOD/SCID/JAK3null recipients. 
 17
 (A) Bone marrow contained CD33-CD34+ immature hematopoeitic stem cells and 
CD33+ myeloid progenitors. (B) Spleen consisted of both human (hCD45+) and murine 
(mCD45.1+) white blood cells. Human white blood cells consisted of B cells(CD19+ ), T 
cells (CD3+), NK cells (CD3-CD56+) and NKT cells (CD3+CD56-). (C) The majority of 
cells in the thymus were CD4/CD8 double positive thymocytes. The CD3+ spleen cells 
included CD4+ or CD8+ single positive mature T cells. Both CD4+ and CD8+ T cells 
included naïve (CD45RA+CCR7+), central memory (CD45RA-CCR7+), effector 
memory (CD45RA-CCR7-), and terminally differentiated (CD45RA+CCR7-) cells. (D) 
Bone marrow contained CD19+CD20- immature and CD19+CD20+ mature B cells. 
Naïve (CD19+Ig-D+CD38+) to memory (CD19+Ig-D-CD38-) B cell differentiation was 
observed in the spleen. CD138+CD38+CD27+ plasma cells were detected in bone 
marrow. (E) BM contained hCD45+CD11c+ human DCs. CD11c+ DCs included CD1c+ 
MDC1 and CD141+ MDC2. BM also contained CD123/CD303 double positive human 
plasmacytoid DCs. (F) Immunohistochemistry of engrafted NOD/Scid/Jak3null mouse 
spleen showed follicular structures in CD20+ and CD3+ human lymphocytes. 
 
Figure 4. Proliferative response of spleen cells from engrafted NOD/SCID/JAK3null 
mice.  
Proliferative response of unfractionated splenocytes obtained from 16 weeks old 
NOD/SCID/JAK3null mice. Data shown are mean ± SD of three mice.  
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Supplement 1.
Enrichment of CD34+ cells by MACS
Pre MACS Post MACS
CD
3
SS
C
0.92% 91.4%
91.6%
3.4%
CD34CD34
Percent of CD34+ cells were 0.3-1.5% / cord blood derived 
mononuclear cells.
Cord blood derived mononuclear cells include 0.3-1.5 % of CD34+ 
cells. We used the CD34+ cells when the purity of CD34+ cells are 
>90% and contaminated CD3+ cells are <5%.
